UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 142

Sortiert nach

Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction

Stem cells (Dayton, Ohio), 2008-07, Vol.26 (7), p.1818-1830

2008

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Journal of clinical oncology, 2013-08, Vol.31 (24), p.3034-3043

2013

Volltextzugriff (PDF)

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma

Current radiopharmaceuticals, 2018-01, Vol.11 (1), p.14

2018

Volltextzugriff (PDF)

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Journal of clinical oncology, 2008-01, Vol.26 (3), p.399-405

2008

Volltextzugriff (PDF)

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Clinical cancer research, 2017-10, Vol.23 (20), p.6062-6069

2017

Volltextzugriff (PDF)

Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial

Pediatrics (Evanston), 2007-06, Vol.119 (6), p.e1239

2007

Volltextzugriff (PDF)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models

Translational oncology, 2017-08, Vol.10 (4), p.604-611

2017

Volltextzugriff (PDF)

Squalene Selectively Protects Mouse Bone Marrow Progenitors Against Cisplatin and Carboplatin-Induced Cytotoxicity In Vivo Without Protecting Tumor Growth

Neoplasia (New York, N.Y.), 2008-10, Vol.10 (10), p.1105,IN4-1119,IN4

2008

Volltextzugriff (PDF)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Cancers, 2022-06, Vol.14 (12), p.2985

2022

Volltextzugriff (PDF)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models

Translational oncology, 2018-08, Vol.11 (4), p.911-919

2018

Volltextzugriff (PDF)

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Clinical cancer research, 2006-09, Vol.12 (17), p.5190-5198

2006

Volltextzugriff (PDF)

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

Neoplasia (New York, N.Y.), 2009-05, Vol.11 (5), p.426-435

2009

Volltextzugriff (PDF)

Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid

Oncogene, 2005-12, Vol.24 (54), p.8025-8037

2005

Volltextzugriff (PDF)

Tissue Microenvironment Modulates CXCR4 Expression and Tumor Metastasis in Neuroblastoma

Neoplasia (New York, N.Y.), 2007-01, Vol.9 (1), p.36-46

2007

Volltextzugriff (PDF)

Functional expression of the multidrug resistance protein 1 in microglia

The Journal of pharmacology and experimental therapeutics, 2003-10, Vol.307 (1), p.282

2003

Volltextzugriff (PDF)

Thymic mucosa-associated lymphoid tissue lymphoma in an adolescent girl

Journal of pediatric hematology/oncology, 2012-10, Vol.34 (7), p.552-555

2012

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study

Clinical cancer research, 2005-01, Vol.11 (2), p.672-677

2005

Volltextzugriff (PDF)

Safety of a Bioactive Polyphenol Dietary Supplement in Pediatric Subjects with Acute Diarrhoea

International Journal of Pediatrics, 2015-01, Vol.2015, p.387159-10

2015

Volltextzugriff (PDF)

Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

Clinical cancer research, 2013-11, Vol.19 (21), p.5972-5983

2013

Volltextzugriff (PDF)

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

Clinical cancer research, 2016-06, Vol.22 (11), p.2697-2708

2016

Volltextzugriff (PDF)

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study

Canadian journal of kidney health and disease, 2017-02, Vol.4

2017

Volltextzugriff (PDF)

Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy

Journal of pediatric hematology/oncology, 2013-07, Vol.35 (5), p.337-347

2013

Volltextzugriff (PDF)

Urinary TIMP-2IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin

Pediatric nephrology (Berlin, West), 2024-01, Vol.39 (1), p.269-282

2024

Volltextzugriff (PDF)

Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease

Clinical cancer research, 2005-01, Vol.11 (2), p.712-719

2005

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(127)

Publikationsform

Artikel
(140)
Berichte
(2)

Sprache

Englisch
(142)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models

Squalene Selectively Protects Mouse Bone Marrow Progenitors Against Cisplatin and Carboplatin-Induced Cytotoxicity In Vivo Without Protecting Tumor Growth

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid

Tissue Microenvironment Modulates CXCR4 Expression and Tumor Metastasis in Neuroblastoma

Functional expression of the multidrug resistance protein 1 in microglia

Thymic mucosa-associated lymphoid tissue lymphoma in an adolescent girl

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study

Safety of a Bioactive Polyphenol Dietary Supplement in Pediatric Subjects with Acute Diarrhoea

Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study

Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy

Urinary TIMP-2IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin

Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease

Translating regenerative medicine therapies in neonatal necrotizing enterocolitis

Suchergebnisse filtern